Treatment approaches are being refined by the primary location of gastroesophageal junction tumors.
Denise Myshko
Advertisement
Senior Editor, OncLive®
Denise Myshko is your editorial contact for the Oncology Business Management section of OncologyLive, as well as the corporate newsletters. She joined OncologyLive in March 2020. Before that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@onclive.com
Articles by Denise Myshko
Treatment approaches are being refined by the primary location of gastroesophageal junction tumors.
The need to adapt effectively and provide consistent care to patients with cancer during the public health threat caused by coronavirus disease 2019 has prompted the expanded use of telehealth.
The need to adapt effectively and provide consistent care to patients with cancer during the public health threat caused by coronavirus disease 2019 has prompted the expanded use of telehealth.
Brian Van Tine, MD, PhD, discusses what tazemetostat’s approval brings to the treatment landscape for patients with epithelioid sarcoma.
Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.
Physicians treating patients with cancer may want to consider postponing surgeries or altering therapy plans because of the threat that the coronavirus poses to this population.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5